Patents by Inventor Darya Burakov

Darya Burakov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12054751
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: August 6, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Publication number: 20240018553
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Application
    Filed: September 6, 2023
    Publication date: January 18, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Patent number: 11788102
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: October 17, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Publication number: 20230322956
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.
    Type: Application
    Filed: November 10, 2022
    Publication date: October 12, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL
  • Publication number: 20230304062
    Abstract: Compositions and methods for the transcription of polynucleotide sequences encoding polypeptides in cells are provided. The cells and methods provided are useful for controlling expression of polypeptides for a wide variety of purposes.
    Type: Application
    Filed: October 18, 2022
    Publication date: September 28, 2023
    Inventors: Yu Zhao, Michael Goren, Darya Burakov, Gang Chen
  • Publication number: 20230295583
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Application
    Filed: December 15, 2022
    Publication date: September 21, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Publication number: 20230287460
    Abstract: The present inventions provide mammalian cells that comprise multiple Stable Integration Sites. The inventions provide sites introduced genomically into a Genomic Safe Harbor and introduced genomically outside of that particular Genomic Safe Harbor, including but not limited to another Genomic Safe Harbor. Polynucleotides of interest that encode polypeptides or RNAs of interest can be inserted into the Stable Integration Sites provided according to the inventions. The cells and methods of the inventions can be used for the high yield production of any protein, including viral proteins. Additionally, the cells and methods of the inventions are useful for production of viral vectors, such as AAV, antibodies and other proteins.
    Type: Application
    Filed: October 18, 2022
    Publication date: September 14, 2023
    Inventors: Michael Goren, Darya Burakov, Gang Chen, Yu Zhao, Dipali Deshpande
  • Publication number: 20230193312
    Abstract: The present inventions provide eukaryotic cells, such as mammalian cells, that comprise adeno-associated virus (AAV) polynucleotides, including AAV capsid proteins (Cap), and are capable of expressing the polypeptides encoded by the AAV polynucleotides, and thereby are capable of producing AAV, including recombinant AAV. The eukaryotic cells also may comprise adenovirus (Ad) polynucleotides. The present inventions also provide methods of expressing AAV polynucleotides, as well as Ad polynucleotides, in eukaryotic cells, such as CHO cells, HEK 293 and BHK cells. The present inventions further provides other products and methods described herein.
    Type: Application
    Filed: October 18, 2022
    Publication date: June 22, 2023
    Inventors: Michael Goren, Yu Zhao, Alexandros Strikoudis, Darya Burakov, Gang Chen
  • Publication number: 20230130799
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.
    Type: Application
    Filed: September 28, 2022
    Publication date: April 27, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL, Yu ZHAO
  • Patent number: 11560550
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: January 24, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Patent number: 11530277
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: December 20, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl
  • Patent number: 11512144
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: November 29, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl, Yu Zhao
  • Patent number: 11268109
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: March 8, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Publication number: 20210340564
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 4, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Publication number: 20210254022
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 19, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Patent number: 11085053
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Publication number: 20210171984
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Application
    Filed: February 12, 2021
    Publication date: June 10, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Publication number: 20210009714
    Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
    Type: Application
    Filed: September 18, 2020
    Publication date: January 14, 2021
    Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
  • Patent number: 10611831
    Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: April 7, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
  • Patent number: RE48651
    Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: July 20, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gang Chen, Darya Burakov, Dipali Deshpande